HONG KONG – As Genor Biopharma Co. Ltd. prepares to move forward with clinical trials for biosimilar Remicade (infliximab, Johnson & Johnson) along a traditional regulatory pathway, regulators in China are still considering an approval pathway specific to biosimilars. While such a pathway would be welcome, it may not necessarily translate into faster approval times.

HONG KONG – In the wake of a pair of deals in just two months that would expand its European footprint, Chinese biopharmaceutical company 3SBio Inc. is getting ready for an initial public offering (IPO) in Hong Kong.

HONG KONG – Shanghai-based Cellular Biomedicine Group Inc. (CBMG), having gotten its start in autologous stem cells has strengthened its position in another area of regenerative cellular therapy, cancer immuno-oncology, with the acquisition of chimeric antigen receptor T-cell (CAR-T) technology and data from the People's Liberation Army General Hospital (PLAGH) in Beijing.

HONG KONG – South Korea's Ministry of Food and Drug Safety (MFDS) has approved the country's first tissue-specific osteoarthritis drug, which its manufacturer hopes will soon grab 10 percent of the Korean arthritis market.

TAIPEI, Taiwan – Biologic drugs are so difficult to make that they are almost impossible to counterfeit, but that does not mean that they are immune to the onslaught of fake products. And yet clamping down on fake biologics can be hard and expensive to do, not to mention that simply identifying fake products after they have been used can be quite difficult.

HONG KONG, China – As Genor Biopharma Co. Ltd. prepares to move forward with clinical trials for biosimilar Remicade (infliximab, Johnson & Johnson) along a traditional regulatory pathway, regulators in China are still considering an approval pathway specific to biosimilars.

HONG KONG – A Chinese clinical trial site management organization (SMO) is getting into monoclonal antibodies (MAbs) after acquiring the global development and licensing rights of drug candidates developed by Chinese academic researchers.

HONG KONG – Looking to position itself as the biggest player in the rapidly growing traditional Chinese medicine (TCM) market in China, the TCM arm of Chinese state-owned Sinopharm Group is planning on a $1.3 billion acquisition of an industry rival and the sale of a biotech subsidiary to channel resources to the development of its TCM business, a move that will help consolidate the market.

HONG KONG – A Chinese clinical trial site management organization (SMO) is getting into monoclonal antibodies (mAbs) after acquiring the global development and licensing rights of drug candidates developed by Chinese academic researchers.